MediciNova, Inc. 2015 Form 10-K Summary
Business context and reporting period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs, primarily for the U.S. market. The filing covers the fiscal year ended December 31, 2015; it is an annual report rather than a quarterly filing. The company had no approved products or commercial product revenue and had 10 full-time employees.
- Lead programs: MN-166 (ibudilast) for progressive multiple sclerosis, ALS and substance dependence; MN-001 (tipelukast) for NASH and idiopathic pulmonary fibrosis.
- Additional programs: MN-221 (bedoradrine) for acute asthma exacerbations and MN-029 (denibulin) for solid tumors.
- All product candidates remained in development and required additional clinical, regulatory and financing support.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research, development and patent expense | $3.0 million | $3.3 million | Down $0.3 million |
| General and administrative expense | $5.8 million | $6.0 million | Down $0.2 million |
| Total operating expenses | $8.8 million | $9.2 million | Down $0.4 million |
| Operating loss | $8.8 million | $9.2 million | Improved $0.4 million |
| Net loss | $8.8 million | $9.2 million | Improved $0.4 million |
| Basic and diluted loss per share | $0.33 | $0.38 | Improved $0.05 |
| Net cash used in operating activities | $7.2 million | Cash provided of $0.8 million | Negative swing of $8.0 million |
| Cash and cash equivalents | $22.1 million | $11.7 million | Up $10.4 million |
| Working capital | $21.2 million | $10.5 million | Up $10.7 million |
There was no meaningful revenue or profit margin because the company had no product sales or recognized revenue. The operating loss was effectively equal to operating expenses. The company reported no outstanding debt and only nominal interest expense. Total assets were $37.9 million, total liabilities were $5.2 million and stockholders’ equity was $32.8 million at year-end. The accumulated deficit was $319.4 million.
Management stated that available working capital was sufficient to fund operations into the second half of 2017, although additional capital would be required to support expanded clinical development. Future funding could come from equity, debt, collaborations or licensing transactions, but availability and terms were uncertain.
Material changes versus the prior comparable period
- Operating expenses declined 4% year over year, primarily because of lower patent and external development costs. Share-based compensation increased to $2.0 million from $1.6 million.
- Research and development expense decreased to $3.0 million from $3.3 million. MN-166 external development expense declined to $0.8 million from $1.1 million, while R&D personnel expense increased to $1.4 million from $1.2 million.
- Operating cash flow deteriorated substantially, from $0.8 million of cash provided in 2014 to $7.2 million used in 2015. The 2014 result benefited from collection of a $6.0 million receivable related to a Genzyme agreement.
- Cash increased due primarily to financing activity. The company raised approximately $16.0 million net from a public offering of 5.0 million shares and approximately $0.7 million net through its prior at-the-market program, and received $0.9 million from warrant exercises.
- Common shares outstanding increased to approximately 30.0 million at year-end from 24.4 million at December 31, 2014, creating dilution risk.
Clinical, strategic and regulatory outlook
- The Phase 2 progressive MS SPRINT-MS trial of MN-166 completed randomization of 255 subjects in June 2015 and was expected to complete in 2017.
- The ALS program expanded to include advanced patients using non-invasive ventilation. The FDA granted Fast Track designation for MN-166 in ALS in December 2015; interim safety monitoring had not identified material concerns.
- MN-166 received FDA orphan-drug designation for Krabbe disease and, after year-end, Rare Pediatric Disease designation for Type 1 early infantile Krabbe disease. The filing also disclosed a February 2016 collaboration with Massachusetts General Hospital for an ALS biomarker study.
- For alcohol dependence, MN-166 reduced basal daily alcohol craving in a 24-subject study but did not reduce cue- or stress-induced craving. The company reported that the study was safe and well tolerated.
- MN-001 had an open IND and FDA-approved Phase 2 protocols for NASH, including a hypertriglyceridemia-focused study initiated in November 2015. A Phase 2 IPF trial was initiated at Penn State in October 2015.
- MN-001 received Fast Track designation for NASH with fibrosis and IPF, and orphan-drug designation for IPF.
- Further development of MN-221 was partner-dependent after FDA feedback that a pivotal trial should use a clinical outcome such as reduced hospitalization. MN-221 did not meet its primary Phase 2b FEV1 endpoint, although secondary signals included reduced hospital admissions.
- Management intended to seek strategic partners after proof-of-concept Phase 2 trials and to use grant-funded or investigator-sponsored trials where possible. The company had no sales or marketing capabilities and expected to rely on partners for commercialization.
Risks, contingencies and unusual items
- The company expected continued substantial losses and stated that, without additional capital, it might need to delay, scale back, out-license or sell programs, or cease operations.
- All candidates remained subject to clinical failure, enrollment delays, safety findings, regulatory holds, manufacturing problems and uncertain FDA approval.
- Potential future milestone payments under license agreements totaled approximately $60.8 million, comprising $10.0 million for products currently in development and $50.8 million for other products; timing was uncertain. Royalties would also be payable on future sales.
- Operating leases and remaining Kissei research and development obligations totaled approximately $2.8 million, including $2.4 million of research and development services.
- The company relied on third-party manufacturers, contract research organizations and clinical investigators and had no internal manufacturing, laboratory or commercial infrastructure.
- Patent protection was limited for MN-166 and MN-001 because composition-of-matter patents had expired; competitors could potentially develop products containing the same active ingredients without infringing method-of-use or other patents.
- The company’s 50% investment in Zhejiang Sunmy, a Chinese joint venture intended to develop MN-221, was accounted for under the equity method. No sublicense of MN-221 had been executed, and the joint venture’s ability to proceed was uncertain.
- At December 31, 2015, outstanding warrants covered approximately 3.4 million shares, including 2.34 million warrants expiring March 29, 2016. Subsequent to year-end, the company received approximately $0.4 million from warrant exercises and $40,000 from option exercises.
- Management and BDO USA, LLP reported effective disclosure controls and internal control over financial reporting. BDO issued unqualified audit opinions.
Important facts for investors to verify
- Whether the company can maintain sufficient liquidity beyond the stated second-half-2017 runway without substantial equity dilution, debt or partnering proceeds.
- Progress, enrollment, safety results and efficacy outcomes for SPRINT-MS, ALS, NASH and IPF trials, including the timing and quality of final data.
- Whether any product candidate advances to pivotal trials, receives FDA approval or generates licensing or milestone revenue.
- The status and terms of the Zhejiang Sunmy MN-221 sublicense and the company’s ability to monetize or partner its pipeline.
- Exercise, expiration and potential dilution from outstanding warrants, stock options, preferred-stock conversion rights and the $30 million at-the-market facility.
- The remaining Kissei deferred revenue and service obligations, potential license milestones, royalties and other contractual commitments.
- Patent-term and market-exclusivity protection for MN-166 and MN-001, particularly given the absence of composition-of-matter protection for their active ingredients.